Changing Fortunes of Next-Gen Sequencing's MDx Apps

Ambry may change platforms for its prenatal screen; Helicos has shed half its staff and may shut down if it can't find fresh cash; and Sequenom must choose between Illumina's and ABI's sequencers for its Downs assay.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.